Thermo Fisher Scientific Bioproduction Articles

  1. Impact Of Media, Stirred-Tank Bioreactors On Cell Therapy Manufacturing 10/14/2022

    Rocking motion bioreactors have long been the mainstay in T-cell therapy, but stirred-tank bioreactors have garnered a lot of excitement because of several potential advantages.

  2. Deliver Product Quality, Enhance Productivity In CHO-K1, CHO-S Cells 6/20/2022

    Early identification of a robust, commercially available, optimized platform medium and cell line–specific feed could be the keys to achieving strong productivity and delivering product to market more rapidly.

  3. Improve Productivity In CHO-K1, CHO-S, And DG44 Cells 4/18/2022

    This commercially available platform can enhance process productivity and reduce development time, thereby enabling potential reductions in manufacturing costs and accelerating time-to-market.

  4. Single-Use Solutions For Research And Process Development 4/12/2022

    Can supply chain assurance be maintained while offering an array of possibilities to achieve complex process designs? Learn if you could benefit from a modularized, standardized single-use manifold design.

  5. Reducing Risk During CAR T Cell Therapy Development And Manufacture 1/26/2022

    It is essential to identify potential areas for optimization early in CAR T cell therapy development—particularly with respect to equipment, reagents, and analytics.

  6. Diploid Serum-Reduced Medium System Supports Viral Production 10/21/2021

    Results demonstrate that the system can enable vaccine manufacturers to reduce the use of FBS while achieving potential increases in viral specific productivity with diploid cells.

  7. Reduce Or Eliminate Serum Use In Vaccine Production 10/21/2021

    The use of this Diploid Growth Serum-Reduced Medium (SRM) helps vaccine manufacturers using diploid cells meet their production forecasts while reducing production costs and serum use.

  8. Optimize Allogeneic Workflow, Cell Proliferation 8/17/2021

    This application note outlines the capabilities of CTS OpTmizer Pro SFM compared with a control medium in both diseased patients’ and healthy donors’ cells.

  9. Human Regulatory T Cell Expansion And Measurement Of Function 8/17/2021

    Regulatory T cells (Tregs) are a subpopulation of T cells with the unique ability to suppress the activation of effector T cells and thereby prevent T cell function. This application note describes an optimized protocol for activation and expansion of flow-sorted Tregs with Gibco™ CTS™ Dynabeads™ Treg Xpander.

  10. Bacto CD Supreme FPM Consistently Supports Higher Growth And Plasmid Production In E. coli 8/12/2021

    Traditional microbial media for E. coli often contain animal-origin components and are complex. Stemmed from an overall industry drive to develop animal origin–free (AOF) and chemically defined (CD) media, Gibco™ Bacto™ CD Supreme Fermentation Production Medium (FPM) supports process flexibility and consistency in production. Read the results of a head-to-head comparison between Bacto CD Supreme FPM and Terrific Broth (TB), a traditional microbial medium.